The emerging landscape of the India pharmaceuticals is witnessing significant interest on Retatrutide, a novel dual GIP and GLP-1 receptor exhibiting potential for metabolic disorders. This molecule is generating considerable excitement within the pharmaceutical community, particularly as Indian com